CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

Exodus Recovery Ctr-Brotman

TotalDrugmart.com

TotalDrugmart.com is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.

Indicus Pharma

Indicus Pharma is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spinal Elements

Spinal Elements, Inc. is an innovative spine technology company that delivers new standards in spine surgery. Spinal Elements, previously Amendia.